机译:经过两次以上患者的经常性或转移性SCLC患者的两次或更多行患者:keynote-028和keynote-158研究结果
Yonsei Univ Coll Med Yonsei Canc Ctr Dept Med Oncol 50-1 Yonsei Ro Seoul 03722 South Korea;
Univ Texas MD Anderson Canc Ctr Dept Invest Canc Therapeut Houston TX 77030 USA;
12 Octubre Univ Hosp Dept Med Oncol Madrid Spain;
Netherlands Canc Inst Div Pharmacol Amsterdam Netherlands;
Chris OBrien Lifehouse Med Oncol Camperdown NSW Australia;
Jewish Gen Hosp Segal Canc Ctr Montreal PQ Canada;
Inst Univ Canc Oncopole Inst Claudius Regaud Dept Oncol Toulouse France;
Blacktown Hosp Western Sydney Local Hlth Dist Blacktown NSW Australia;
Gustave Roussy Thorac Grp Dept Med Oncol Villejuif France;
Meir Med Ctr Oncol Kefar Sava Israel;
Rabin Med Ctr Davidoff Canc Ctr Petah Tiqwa Israel;
Indiana Univ Simon Canc Ctr Indianapolis IN 46204 USA;
Ctr Oscar Lambret Dept Med Oncol Lille France;
Rutgers Canc Inst New Jersey Dev Therapeut New Brunswick NJ USA;
Vall dHebron Inst Oncol Dept Med Oncol Barcelona Spain;
Inst Cancerol Ouest Nantes France;
Seoul Natl Univ Hosp Coll Med Seoul South Korea;
Merck Sharp &
Dohme Corp Kenilworth NJ USA;
Merck Sharp &
Dohme Corp Kenilworth NJ USA;
Merck Sharp &
Dohme Corp Kenilworth NJ USA;
Dana Farber Canc Inst Boston MA 02115 USA;
Third-line therapy; Pembrolizumab; SCLC; Immunotherapy;
机译:经过两次以上患者的经常性或转移性SCLC患者的两次或更多行患者:keynote-028和keynote-158研究结果
机译:单独或用化疗与化疗与化学疗法进行复发性或转移性鳞状细胞癌(Keynote-048):随机开放标签,第3阶段研究(Vol 394,PG 1915,2019)
机译:单独或用化疗与化学疗法与化疗进行复发性或转移性鳞状细胞癌的头部和颈部(Keynote-048):随机,开放标签,第3期研究
机译:HIFU治疗晚期骨盆癌复发/转移性癌症的初步临床研究
机译:Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
机译:派姆单抗治疗复发性局部晚期或转移性胃或胃食管连接癌患者:基于证据的治疗位置回顾
机译:ATIM-35。患有复发性PD-L1阳性胶质母细胞瘤多形(GBM)患者蛋白质IB keynote-028多群蛋白疗法的Muliforme(GBM)的结果